ATE545867T1 - I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom - Google Patents

I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom

Info

Publication number
ATE545867T1
ATE545867T1 AT08826976T AT08826976T ATE545867T1 AT E545867 T1 ATE545867 T1 AT E545867T1 AT 08826976 T AT08826976 T AT 08826976T AT 08826976 T AT08826976 T AT 08826976T AT E545867 T1 ATE545867 T1 AT E545867T1
Authority
AT
Austria
Prior art keywords
plastin
test method
vitro diagnosis
colorectal carcinoma
diagnosis
Prior art date
Application number
AT08826976T
Other languages
English (en)
Inventor
Monique Arpin
Nicole Battail-Poirot
Corinne Beaulieu
Jean-Philippe Charrier
Genevieve Choquet-Kastylevsky
Original Assignee
Biomerieux Sa
Centre Nat Rech Scient
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Sa, Centre Nat Rech Scient, Inst Curie filed Critical Biomerieux Sa
Application granted granted Critical
Publication of ATE545867T1 publication Critical patent/ATE545867T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08826976T 2007-07-19 2008-07-10 I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom ATE545867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0705198A FR2919061B1 (fr) 2007-07-19 2007-07-19 Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
PCT/FR2008/051294 WO2009019369A2 (fr) 2007-07-19 2008-07-10 Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal

Publications (1)

Publication Number Publication Date
ATE545867T1 true ATE545867T1 (de) 2012-03-15

Family

ID=39092068

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08826976T ATE545867T1 (de) 2007-07-19 2008-07-10 I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom

Country Status (9)

Country Link
US (1) US8445211B2 (de)
EP (1) EP2171466B1 (de)
JP (1) JP5417327B2 (de)
CN (1) CN101765774B (de)
AT (1) ATE545867T1 (de)
AU (1) AU2008285558B2 (de)
CA (1) CA2695191C (de)
FR (1) FR2919061B1 (de)
WO (1) WO2009019369A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
US20120244141A1 (en) * 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US20120172244A1 (en) 2010-12-20 2012-07-05 Steven Buechler Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
EP2655663A4 (de) * 2010-12-20 2015-01-28 Univ Notre Dame Du Lac Biomarker und ihre verwendung für prognose- und behandlungsstrategien für rechtsseitiges und linksseitiges kolonkarzinom
FR3001805B1 (fr) 2013-02-01 2015-02-20 Biomerieux Sa Procede de detection d'un cancer colorectal
CN108611368A (zh) * 2018-05-04 2018-10-02 国家纳米科学中心 一种pls3-abd2重组蛋白的制备方法
CN113999817B (zh) * 2021-10-28 2022-10-21 杭州博茵生物技术有限公司 半乳糖凝集素-3鼠杂交瘤细胞、单克隆抗体、检测试剂盒及检测方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920484A1 (de) 1979-05-21 1980-12-04 Bosch Gmbh Robert Messeinrichtung mit magnetischem kreis zum messen eines gleichstroms
US4529931A (en) * 1983-04-07 1985-07-16 Ford Motor Company Single-coil current measuring circuit
US5360715A (en) * 1988-06-07 1994-11-01 California Institute Of Technology Plastin isoforms and their uses
US5002870A (en) * 1988-06-07 1991-03-26 California Institute For Medical Research Plastin isoforms and their use
JP2816175B2 (ja) 1989-04-28 1998-10-27 三菱電機株式会社 直流電流測定装置
US5223789A (en) * 1989-06-23 1993-06-29 Fuji Electric Co., Ltd. AC/DC current detecting method
JPH0464068A (ja) 1990-07-02 1992-02-28 Fuji Electric Co Ltd 直流電流検出方法
CA2054149A1 (en) 1990-10-29 1992-04-30 Eric Pringault Villin gene promoter sequence and its use in vectors, transformed mammalian cell lines, transgenic animals, and cell lines derived from the animals
US6291205B1 (en) 1992-06-12 2001-09-18 Merck & Co., Inc. Method of increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae
US6001632A (en) * 1996-05-15 1999-12-14 Incyte Pharmaceuticals, Inc. Human protein disulfide isomerase
DE19642472A1 (de) 1996-10-15 1998-04-16 Abb Research Ltd Flußkompensierter Stromsensor
CA2353546C (en) 1998-12-01 2009-05-19 Wrair Diagnosis of stage or aggressiveness of cancer
JP2002536995A (ja) 1999-02-22 2002-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド 結腸の疾患に関連する遺伝子
EP1171771B1 (de) * 1999-04-09 2005-06-29 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2002020731A2 (en) 2000-09-08 2002-03-14 Bayer Aktiengesellschaft Regulation of human protein disulfide isomerase-like enzyme
AU2001294943A1 (en) * 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
AU2002232407A1 (en) * 2000-10-30 2002-05-15 Board Of Regents, The University Of Texas System Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof
US20030082533A1 (en) * 2001-01-26 2003-05-01 Henry Yue Intelectin
US20030087818A1 (en) * 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
GB0208331D0 (en) 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ES2316997T3 (es) * 2003-07-21 2009-04-16 F. Hoffmann-La Roche Ag Uso de la proteina proteinasa 3 (prn3) y del inhibidor de la elastasa leucocitaria (ileu) como un marcador para el cancer colorrectal.
WO2005015218A1 (en) 2003-07-21 2005-02-17 Roche Diagnostics Gmbh Use of proteins proteinase 3 (prn3) and leukocyte elastase inhibitor (ileu) as a marker for colorectal cancer
WO2005015226A1 (en) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Use of protein t-plastin (plst) as a marker for colorectal cancer
EP1723428A2 (de) * 2004-02-19 2006-11-22 Yale University Corporation Identifizierung von krebsprotein-biomarkern unter verwendung von proteomtechniken
CN1669585A (zh) * 2004-03-19 2005-09-21 王健伟 一种肿瘤治疗剂及其用途
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
WO2006015079A2 (en) 2004-07-27 2006-02-09 Yale University Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
AT500719B1 (de) 2004-09-08 2010-06-15 Red Bull Gmbh Chaperone als tumormarker
WO2006074360A2 (en) 2005-01-06 2006-07-13 Eastern Virginia Medical School Apolipoprotein a-ii isoform as a biomarker for prostate cancer
US20060192550A1 (en) 2005-02-25 2006-08-31 Sandquist David A Current sensor with magnetic toroid single frequency detection scheme
KR101708544B1 (ko) * 2005-04-15 2017-02-20 에피제노믹스 아게 세포 증식 질환을 분석하기 위한 방법 및 핵산
EP1724586A3 (de) 2005-05-21 2007-07-04 ProteoSys AG Annexin für Krebsrisikomanagement
US8465929B2 (en) 2005-06-24 2013-06-18 Vermillion, Inc. Biomarkers for ovarian cancer
EP2166357A1 (de) 2005-08-18 2010-03-24 Zadec Aps Proteinmarker zur Diagnostizierung eines kolorektalen Karzinoms
EP1775590A1 (de) 2005-10-11 2007-04-18 Laboratorios S.A.L.V.A.T., S.A. Nicht invasive in vitro Methode zur Detektion von Transitionalzellkarzinomen der Harnblase
CN1967246A (zh) 2005-11-18 2007-05-23 上海中科新生命生物科技有限公司 酰化氨基酸水解酶1及其抗体检测肝癌的应用
EP1971359A2 (de) 2005-12-16 2008-09-24 Electrophoretics Limited Diagnose und prognose von kolorektal-karzinom
CA2629071A1 (en) * 2005-12-21 2007-06-28 F. Hoffmann-La Roche Ag Method of assessing colorectal cancer by measuring hemoglobin and m2-pk in a stool sample
CN101346628A (zh) * 2005-12-22 2009-01-14 霍夫曼-拉罗奇有限公司 包含骨桥蛋白和癌胚抗原的标记物组合在结肠直肠癌的评估中的用途
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8263344B2 (en) 2006-09-08 2012-09-11 Institut Gustave Roussy Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
US20100111973A1 (en) 2006-09-22 2010-05-06 Glenn Dranoff Methods for treating mica-related disorders
EP2581455A3 (de) 2008-01-17 2013-07-10 Suregene LLC Genetische Marker von Geisteskrankheiten
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal

Also Published As

Publication number Publication date
AU2008285558B2 (en) 2014-05-08
US8445211B2 (en) 2013-05-21
WO2009019369A2 (fr) 2009-02-12
FR2919061A1 (fr) 2009-01-23
CN101765774B (zh) 2013-11-06
EP2171466B1 (de) 2012-02-15
CA2695191C (fr) 2019-06-25
JP5417327B2 (ja) 2014-02-12
JP2010533854A (ja) 2010-10-28
EP2171466A2 (de) 2010-04-07
WO2009019369A3 (fr) 2009-04-09
CA2695191A1 (fr) 2009-02-12
AU2008285558A1 (en) 2009-02-12
CN101765774A (zh) 2010-06-30
US20100136571A1 (en) 2010-06-03
FR2919061B1 (fr) 2009-10-02

Similar Documents

Publication Publication Date Title
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
EP4293358A3 (de) Flüchtige organische verbindungen als krebs biomarker
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
EP4282405A3 (de) Nachweis von krebs-biomarkern mittels nanopartikeln
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
EP2212700B8 (de) Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
TW200626900A (en) Wnt proteins and detection and treatment of cancer
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
DE60306517D1 (de) Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
WO2012166700A3 (en) Molecular profiling of a lethal tumor microenvironment
MX2012000041A (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.
ATE531822T1 (de) Diagnose von prostatakrebs